AxoGen (NASDAQ:AXGN) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of AxoGen (NASDAQ:AXGN – Get Rating) in a report released on Thursday. The brokerage set a “buy” rating on the medical equipment provider’s stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $20.00 target price on shares of AxoGen in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $17.00.

AxoGen Stock Performance

Shares of NASDAQ:AXGN opened at $8.22 on Thursday. The firm has a market cap of $350.19 million, a PE ratio of -12.09 and a beta of 0.54. The firm’s 50 day simple moving average is $9.16 and its 200-day simple moving average is $10.32. AxoGen has a one year low of $6.87 and a one year high of $13.66. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.54 and a current ratio of 4.35.

Insider Transactions at AxoGen

In other news, CFO Peter J. Mariani sold 20,939 shares of AxoGen stock in a transaction on Thursday, January 26th. The shares were sold at an average price of $9.90, for a total transaction of $207,296.10. Following the completion of the sale, the chief financial officer now directly owns 42,108 shares in the company, valued at $416,869.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Peter J. Mariani sold 14,320 shares of AxoGen stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $9.55, for a total transaction of $136,756.00. Following the completion of the sale, the chief financial officer now directly owns 55,555 shares in the company, valued at $530,550.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Peter J. Mariani sold 20,939 shares of AxoGen stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $9.90, for a total transaction of $207,296.10. Following the sale, the chief financial officer now owns 42,108 shares of the company’s stock, valued at $416,869.20. The disclosure for this sale can be found here. Insiders own 7.51% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. HighMark Wealth Management LLC raised its holdings in shares of AxoGen by 851.1% during the third quarter. HighMark Wealth Management LLC now owns 2,235 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,000 shares during the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of AxoGen during the third quarter worth $27,000. Lazard Asset Management LLC raised its holdings in shares of AxoGen by 1,282.6% during the first quarter. Lazard Asset Management LLC now owns 5,088 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 4,720 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of AxoGen by 610.2% during the third quarter. Royal Bank of Canada now owns 6,129 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 5,266 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of AxoGen by 139.2% during the third quarter. Tower Research Capital LLC TRC now owns 8,909 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 5,184 shares during the last quarter. Hedge funds and other institutional investors own 76.22% of the company’s stock.

About AxoGen

(Get Rating)

Axogen, Inc engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator.